The diagnosis of 'ALL with maturation' (ALLm) is proposed. One hundred and one patients with untreated ALL were entered into this study. The diagnosis of ALLm was made when more than 20% of all nucleated elements in the bone marrow 
Introduction
Acute lymphoblastic leukemia (ALL) is a common malignant tumor especially in children and substantial improvement has been achieved during the last two decades. However, adult ALL has had an inferior outcome in comparison with childhood ALL. Most chemotherapeutic agents for ALL inhibit growth of tumor cells in the cell cycle and do not affect the cells in G0 phase. Therefore, the growth fraction of leukemic cells could have a profound effect on their susceptibility to chemotherapy. Several prognostic factors, for example, age, FAB classification, white blood cell (WBC) count, immunological subtype, serum lactic dehydrogenase (LD), p53 expression, karyotype and others have been found to have a major influence on remission or survival rate. [1] [2] [3] [4] However, how future results can be improved is not certain. Recently, multidrug resistance (MDR) caused by the P-glycoprotein (Pgp) has been documented in acute leukemias. [5] [6] [7] We have experienced 19 cases of ALL where leukemic cells showed morphological maturation beyond prolymphocytes. However, the clinical significance of morphologic maturation of the leukemic cells in ALL has not been evaluated and what makes the leukemic cells morphologically mature is not clear. Cell proliferation in situ was analyzed by immunohistochemistry of DNA topoisomerase II␣ (TopoII). We investigated clinical response to induction chemotherapy and compared other prognostic factors including hematological features, immunophenotypes, Pgp expression, P53 protein accumulation and chromosome findings of this group to those of a typical ALL group.
Materials and methods

Patient selection
One hundred and one patients who presented at St Mary's Hospital consecutively during a 2-year period up to November 1996 were studied. For diagnosis of ALL we used standard cytological and histochemical examination of bone marrow and blood smears according to the French-AmericanBritish (FAB) classification. 8 The diagnosis of 'ALL with maturation' (ALLm) was made when more than 20% of all nucleated elements in the bone marrow showed maturation beyond prolymphocytes by light microscopic examination. The mature-appearing leukemic cells were smaller than lymphoblasts and had condensed nuclear chromatins without visible nucleoli like mature lymphocytes (Figure 1 ). The number of ALLm cases was 19 (18.8%) of 101 ALL cases. The other 82 ALL cases (81.2%) showing less than 20% mature cells were classified as 'typical ALL' (ALLt), for convenience. The clinical information and initial laboratory data are shown in Table I . The mean age at presentation of all ALLm patients was 29 ± 18 and was older than that of ALLt, 18 ± 16 (P = 0.015). The number of patients less than 10 years old at presentation was three of 19 (15.8%) ALLm and 31 of 82 (37.8%) ALLt patients. Ten of the 19 ALLm patients were males.
Chemotherapy
Chemotherapy was administered according to modified Linker's protocol. 9 Remission was induced with daunorubicin, vincristine, prednisone and L-asparaginase. Patients showing less than 5% blasts in the bone marrow with normal bone marrow cellularity, differential count and normal peripheral blood after 4 weeks induction chemotherapy were considered as complete remission (CR). If the bone marrow on day 28 showed residual leukemia, chemotherapy extended for an additional 2 weeks. Patients not entering CR after 6 weeks induction chemotherapy were regarded as treatment failures. 
Immunophenotype determination
Bone marrow aspirates were used to determine the surface antigen phenotype by means of monoclonal antibodies. In all cases initial bone marrow aspirates were analyzed, and in ALLm cases bone marrow aspirates after induction chemotherapy were also studied. The ALL panel was CD2, CD3, CD10, CD19, CD20, CD22 and CD15 and/or CD33. In some cases, CD34, HLA-DR and Tdt were also studied. All monoclonal antibodies were purchased from Becton Dickinson (San Jose, CA, USA). The samples were analyzed using direct immunofluorescent staining and flow cytometer (FACSCAN; Becton Dickinson), except for Tdt analysis. For Tdt analysis, the cells were fixed in paraformaldehyde and stained with anti-Tdt followed by incubation with FITC-conjugated goat anti-mouse immunoglobulin. Idiotypic-negative control was used to set markers. The criterion for surface marker positivity was expression by more than 20% of the gated leukemic cell population. We tried to analyze mature-appearing leukemic cells separately by gating low forward scattering (FSC) and low side scattering (SSC) cells.
Immunohistochemical staining for TopoII and P53
The paired (initial and after 4 weeks induction chemotherapy) bone marrow needle biopsy specimens were available in 18 ALLm cases and fixed in 4% buffered formaldehyde for up to 18 h and decalcified. The bone marrow biopsy of 10 ALLt cases that achieved CR after 4 weeks induction chemotherapy were stained together with ALLm cases. The formaldehydefixed, paraffin-embedded blocks were cut into 4 m thicknesses and deparaffinized in xylene and rehydrated. Then all slides were autoclaved in 0.01 M citrate buffer (pH 6.0) at 121°C for 10 min. The endogenous peroxidase activity was blocked by 0.3% (v/v) H 2 O 2 and nonspecific binding was blocked with normal goat serum. The monoclonal antibody to TopoII (Neomarkers, Fremont, CA, USA) and P53 protein (NCL-p53-DO7; Novocastra Laboratories, Newcastle, UK) were diluted 1:50 and the signal was detected with a biotinstreptavidin immunoperoxidase detection method using biotinylated goat anti-mouse IgG and streptavidin conjugated to horseradish peroxidase (Zymed, San Francisco, CA, USA). Bound peroxidase was developed with 3-amino-9-ethylcarbazole (Zymed) at 45°C for 8 min. All slides were counterstained with Meyer's hematoxylin for 10 s. The red staining on the nuclei was regarded as positive staining. Topo II labeling index (TopoLI) was scored by counting positive nuclei among 1000 cells.
Immunohistochemical staining for Pgp
The slides were made and deparaffinized in the same way as for TopoII except for autoclaving. A case of acute monocytic leukemia where leukemic cells showed strong positive reaction to anti-Pgp by flow cytometry was selected and the bone marrow biopsy of this case was used as positive control. The monoclonal antibody to Pgp (JSB-1; Monosan, Uden, The Netherlands) were diluted 1:20 (12.5 g/ml) and the signal was detected similarly as for TopoII. The red staining on the cytoplasmic membrane was considered as positive staining.
Cytogenetic analysis and fluorescent in situ hybridization (FISH) for the bcr/abl gene Cytogenetic analysis was successful in seven cases of ALLm. Bone marrow metaphase spreads were prepared according to previously described techniques. 10 Metaphase preparations were banded with Giemsa stain. Chromosomal abnormalities were described using the conventions proposed in the 1995 International System of Human Cytogenetic Nomenclature. Analyses were regarded as unsuccessful if fewer than 10 metaphases were karyotyped.
For FISH, air-dried bone marrow smears on sialized slides were used. The specimens were available in eight ALLm cases. The cells on the slides were digested with proteinase K (1 g/ml) for 2 min. Target DNA on the slides underwent denaturation in 70% formamide in 2 × SSC solution at 70°C for 3 min. Then the slides were dehydrated in graded ethanol at −20°C and air dried. The minor bcr/abl translocation DNA probe (Oncor, Gaithersburg, MD, USA) was preheated to 37°C in a water bath and 10 l of probe put on each slide and coverslipped. After overnight incubation at 37°C, the slides were washed in 2 × SSC at 72°C for 5 min without agitation. The signals were detected by digoxigenin-rhodamine and biotin-FITC detection kits (Oncor) according to the manufacturer's instructions. Because the signals were small, they were amplified as follows: coverslips were soaked off in 1 × PBD and rabbit anti-sheep antibody and anti-avidin antibody was applied for 20 min at 37°C. After washing in 1 × PBD, the slides were incubated with rhodamine anti-rabbit antibody and fluorescein-labeled avidin for 20 min at 37°C. FISH results were analyzed by three experienced people with a mangification of ×1000 on a fluorescent microscope (Olympus, Tokyo, Japan). The colors of signals were red for the bcr locus on chromosome 22 and green for the abl locus on chromosome 9 and yellow or adjacent red-green double spot for the fused bcr/abl locus. The red and green signals up to one signal diameter apart were scored as fused bcr/abl signal. 11 
Statistical analysis
The study was designed to analyze the differences of immunophenotype, TopoLI, p53 protein accumulation, Pgp expression, karyotype and response to therapy between ALLm and ALLt.
Two independent sample tests of Mann-Whitney U test type were used to compare age distribution and laboratory data in ALLm and ALLt patients. Both failure to achieve CR and death during induction chemotherapy were considered as 'failure to achieve CR'. All reported P values are based on two-sided tests of significance.
Results
Hematological features
The hemoglobin concentration, leukocyte and platelet count for the 19 ALLm patients are given in Table 1 . The highest leukocyte count was 706 000/l and the lowest count was 300/l.
The mean value at presentation was 116 700 ± 202 300, and it was higher although not significant statistically, than that of ALLt patients (54 300 ± 123 800, P = 0.06). The mature-appearing leukemic cells were admixed with lymphoblasts (Figures 1a and b) before induction chemotherapy and only the lymphoblasts disappeared by chemotherapy, the mature-appearing leukemic cells remaining (Figures 1c and d) . The counts of mature-appearing leukemic cells in the bone marrow of ALLm patients at presentation and after induction chemotherapy are given in Table 2 . At presentation mature cell counts in the bone marrow were less than 10% in all ALLt patients. Other laboratory information including hemoglobin, platelet count and serum lactic dehydrogenase of ALLm patients was not different from that of ALLt patients.
Response to induction chemotherapy
Only two of 19 (case Nos 14 and 19, 10.5%) ALLm patients achieved CR after 4 weeks induction chemotherapy. In contrast, 57 of 82 (69.5%) ALLt patients achieved CR after the same induction chemotherapy. Eight of 17 ALLm cases that did not enter CR after 4 weeks induction chemotherapy achieved CR after 2 more weeks chemotherapy. In total, 10 of 19 ALLm cases entered CR after 6 weeks chemotherapy. Case 1 died during induction chemotherapy. The remainder of patients never achieved a CR.
Immunophenotyping results
Fifteen of 18 (83.3%) ALLm cases were B cell lineage and the other three cases (16.7%) were T cell ALL. The matureappearing leukemic cells could not be separated clearly by gating. However, the immunophenotypes of mature-appearing leukemic cells (low FSC, low SSC) and lymphoblasts were the same. After 4 weeks induction chemotherapy bone marrow aspirates showed the same immunophenotype as the previous initial bone marrow. Of 82 ALLt cases, 69 cases (84.1%) were B cell lineage, nine cases (11.0%) were T cell ALL and Table 2 The labeling index of topoisomerase (TopoLI), P53 protein accumulation and count of mature cells beyond prolymphocytes in the bone marrow of ALLm patients at presentation and after 4 weeks induction chemotherapy (in parenthesis)
Case No. Figure 2) . Furthermore, the remaining leukemic cells, mainly mature-appearing leukemic cells, were not labeled with anti-DNA topoisomerase II␣ after chemotherapy. The erythroid precursors found in the bone marrow after chemotherapy showed positive results.
Immunohistochemical staining for P53
Nine of a total of 18 cases (50.0%) of ALLm reacted to the anti-P53 ( Table 2 ). Eight of these positive cases showed positive reaction both before and after induction chemotherapy but case 9 revealed positive reaction only before chemotherapy and negative reaction after chemotherapy. The staining intensity was variable from case to case and from nucleus to nucleus, even in the same case.
Immunohistochemical staining for Pgp
The positive control (acute monocytic leukemia) case showed positive reaction on the cell membrane. however, all the ALLm cases before and after induction chemotherapy and ALLt cases that achieved CR after induction chemotherapy showed negative reaction.
Results of cytogenetic study and FISH for bcr/abl genes Fourteen ALLm samples were sent for cytogenetic analysis and a successful cytogenetic result was obtained in only seven cases (50%). An abnormal clone was detected in three patients (case Nos 9, 10 and 18), and case 10 showed t(9;22)(q34;q22) ( Table 1) . FISH for bcr/abl genes was done on cases 3, 5, 7, 9, 10, 13, 14 and 19. Only two cases (cases 9 and 10) revealed fused bcr/abl signals. Interestingly, case 9 showed complex karyotype without Ph′ chromosome on karyotyping, but about 20% of all nuclei showed bcr/abl fusion on FISH (Figure 3a) . The remaining six cases revealed two red and two green signals in each nucleus (Figure 3b) .
Discussion
We report a relatively common morphologic variant of ALL which has many mature-appearing leukemic cells showing condensed chromatin without visible nucleoli like mature lymphocytes. Adult ALL was reported to have an inferior outcome in comparison to childhood ALL. 12 The mean age at presentation of ALLm was older than ALLt and most ALLm patients were adults. This suggests that the prevalence of ALLm in adults could contribute to the poor prognosis of adult ALL.
Although 10 patients of ALLm entered remission after 6 weeks of chemotherapy, only two patients (10.5%) achieved CR after 4 weeks of induction chemotherapy, which was poor compared with 69.5% of ALLt patients. Furthermore, only the lymphoblasts disappeared by chemotherapy and the matureappearing leukemic cells remained in ALLm. In other words, the chemoresistance of ALLm is caused by chemoresistance of the mature-appearing leukemic cells rather than lymphoblasts. The outcome of patients who required 6 weeks induction chemotherapy to enter remission was reported to be much worse than those who entered remission within 4 weeks of therapy. 9 Five years continuous CR rate of ALL patients who entered remission within 4 weeks of therapy was 48 ± 6%, but that of patients who required 6 weeks induction chemotherapy was 0%. Therefore, because ALLm has a worse prognosis than ALLt, a different therapeutic modality including bone marrow transplantation at first CR could be recommended for ALLm.
Heterogeneity within each subgroup of ALL has been further delineated using monoclonal antibodies to cell surface antigens. However, the prognostic value of immunophenotype of ALL cells, especially T-ALL, is controversial. 9, 13, 14 In this study, immunophenotype of ALLm was not different from ALLt. In other words, the morphologic maturation of ALLm cells was not related to specific immunophenotype.
TopoII is a well known target enzyme of various chemotherapeutic agents. 15 Expression of TopoII has been demonstrated to increase rapidly at the end of the S to G2/M phase and decrease after the completion of mitosis. 16 Recently, it became possible to localize TopoII activity in tumor tissue by immunohistochemistry using paraffin blocks. 17 In this study, we studied TopoLI in ALLm compared with ALLt by immunohistochemistry. The TopoLI of ALLm was much lower than that of ALLt. Furthermore, after chemotherapy, the remaining morphologically mature leukemic cells were not labeled with anti-TopoII. This suggests that the morphologically mature leukemic cells are in resting G0 phase rather than in cell cycle. This could be the reason why ALLm has a poorer response than ALLt. p53 gene is a well known tumor suppressor gene and its product, P53 protein, is accumulated when this gene is mutated or deleted. P53 protein accumulation was found in a poor prognositc group of childhood ALL. 18 In this study, P53 protein accumulation was found in 50% of ALLm cases which is less than the reported frequency. 18 Moreover, one case (case 9) revealed positive reaction only before chemotherapy and not on the remaining mature-appearing leukemic cells after chemotherapy. Therefore, we conclude that P53 protein accumulation is not associated with the morphological maturation of ALLm.
The emergence of multidrug-resistant tumor cells is often related to overexpression of membrane-bound Pgp in acute leukemia. 19 Pgp is coded by the mdr-1 gene and is expressed at different levels in many normal tissues. [20] [21] [22] Resistance to multiple chemotherapeutic agents is a common clinical problem in the treatment of acute leukemia. MDR may occur before primary therapy or be acquired during treatment. The physiological role of Pgp is to control the efflux of drugs from the cell. 23 A promising therapeutic scenario is provided by the finding that certain drugs are available that may reverse Pgp action, thus rendering MDR tumor cells more sensitive to cytostatic drugs. 24 The clinical significance of Pgp expression in ALL is still uncertain. 25, 26 However, several authors have already reported that Pgp overexpression is associated with lower remission rates and poor prognosis. 6 A simple and sensitive method to detect Pgp in tumor cells is provided by immunohistochemical staining with monoclonal antibody. 6 Nuclear chromatin pattern has been reported to be changed in drug-selected human MDR cells and not in other MDR cells without drug selection. 27 However, the ALLm patients in this study were not exposed to any chemotherapeutic drugs before and no ALLm cases showed Pgp expression before induction chemotherapy by immunohistochemistry. This result suggests that the difference of ALLm from ALLt is not due to Pgp expression.
Previous studies have shown that chromosomal abnormalities such as Philadelphia chromosome and t(4;11) are associated with a poor prognosis in both childhood and adult ALL. [28] [29] [30] In this study, only one case showed Philadelphia chromosome among seven karyotyped ALLm cases. Although the number of cases was limited, this result means ALLm is an independent morphologic variant not related to any cytogenetic aberrations.
Another possibility could be the presence of alterations in the structure of the nuclear matrix of mature-appearing leukemic cells. The matrix appears to be a major substance in the maintenance of nuclear shape and organization 31 and leukemic lymphocyte progenitors could generate malignant daughter cells capable of an in vivo maturation. 32 However, what causes this change is not clear.
In conclusion, it is an important fact that ALLm has more leukemic cells in resting G0 phase and this could be the reason why ALLm has a poorer response to chemotherapy than ALLt. Furthermore, it is easy to identify ALLm and additional time or expensive, laborious work, in addition to microscopy of Wright-stained smears, is not necessary. Therefore, we suggest that this category of ALL (ALLm) should be classified separately from ALLt.
